Ap Government Stem Cell Research I created this video with the YouTube Video Editor (http://www.youtube.com/editor) By: Carly Roberts … Continue reading →

Stem Cell Primer Video By: Dr. Max Gomez … Continue reading →

Durham, NC (PRWEB) June 11, 2013 The path to bringing a new drug to market is, simply put, a rocky one. Not only is it estimated to take over 12 years at an average price tag running anywhere between US $800 million and US $2 billion, but more often than not the new drug never makes it through the process. But now a research team reports that it has developed a way to speed up the process. Their work, which involves the creation of a highly stable and sensitive liver stem cell model, is reported in the latest issue of STEM CELLS Translational Medicine. Liver toxicity is the second most common cause of human drug failure, explained David Hay, Ph.D., of the University of Edinburghs MRC Centre for Regenerative Medicine, who led the team made up of university colleagues and scientists from Bristol-Myers Squibb, Princeton, N.J. But one major bottleneck in safety testing new drugs has been finding a routine supply of good quality primary human hepatocytes from the desired genetic background. Scientists have long believed that finding an efficient way to force pluripotent stem cells (PSCs) to develop into hepatocytes liver cells could be the way around the problem. … Continue reading →

Yields optimized stem cell growth and expansion per passage to accelerate research and discovery BOSTON--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific HyClone HyCell-STEM and HyCell-STEM-FF stem cell culture media, designed to optimize the expansion rate of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) per passage for cell culture applications including cell signaling, drug discovery and therapeutic research. The new HyCell-STEM media solutions will be showcased this week at the 11thAnnual International Society for Stem Cell Research (ISSCR) conference at the Boston Convention and Exhibition Center, Booth #637. With the introduction of HyCell-STEM and HyCell-STEM-FF, we are offering researchers solutions that increase the rate of stem cell expansion while preserving cell morphology, stemness and pluripotency. Further, scientists may anticipate outstanding recovery after thaw, following cryopreservation of cells. There are exciting discoveries being made in the stem cell area today, and researchers demand the highest quality products to increase yields and integrity of their cell cultures, said Roberta Morris, business director for Thermo Fisher Scientific. With the introduction of HyCell-STEM and HyCell-STEM-FF, we are offering researchers solutions that increase the rate of stem cell expansion while preserving cell morphology, … Continue reading →

Public release date: 11-Jun-2013 [ | E-mail | Share ] Contact: Tara Womersley tara.womersley@ed.ac.uk 44-131-650-9836 University of Edinburgh Drug development for a range of conditions could be improved with stem cell technology that helps doctors predict the safety and the effectiveness of potential treatments. Medical Research Council scientists at the University of Edinburgh have been able to generate cells in the laboratory that reach the gold standard required by the pharmaceutical industry to test drug safety. The researchers used stem cell technology to generate liver cells which help our bodies to process drugs. They found that the cells were equally effective, reaching the same standard, as cells from human liver tissue currently used to assess drug safety. These human cells used in drug testing are in short supply and vary considerably due to different donors. As a result they are not an ideal source for drug development. The stem cell based technique developed in Edinburgh, addresses these issues by offering a renewable production of uniform liver cells in the laboratory. Dr David Hay of the Medical Research Council (MRC) Centre for Regenerative Medicine at the University of Edinburgh, said: "Differing genetic information plays a key role in how patients' livers … Continue reading →

CARLSBAD, Calif., June 12, 2013 /PRNewswire/ --Life Technologies Corporation (LIFE) today launched the TaqMan hPSC Scorecard Panel, a first-of-its-kind characterization assay that establishes a standardized benchmark against which researchers can now evaluate pluripotency and trilineage differentiation potential in human embryonic (ES) and induced pluripotent stem (iPS) cell lines. Life will showcase the technology during the International Society for Stem Cell Research (ISSCR) conference in Boston June 12-15. Until now, scientists have evaluated pluripotency the potential for ES and iPS cells to differentiate into any cell type with laborious, costly and non-standardized methods that provide ambiguous results. Additionally, their inability to accurately determine cell lines' propensity to differentiate into one of the three primary cell germ layers has contributed to major hurdles that impede stem cell technology from moving into the clinic. The TaqMan hPSC Scorecard Panel, however, relies on a specific range of gene expression levels identified at Harvard University to accurately characterize cell lines in two critical areas: pluripotency and lineage bias. The panel is also being offered with cloud-based software for rapid data analysis and data sharing among research collaborators. "The rapid advancements in stem cell research over the last few years have created a need for more … Continue reading →